BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 17321748)

  • 1. Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease.
    Hemming ML; Selkoe DJ; Farris W
    Neurobiol Dis; 2007 Apr; 26(1):273-81. PubMed ID: 17321748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor.
    Hemming ML; Selkoe DJ
    J Biol Chem; 2005 Nov; 280(45):37644-50. PubMed ID: 16154999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion of Aβ43 to Aβ40 by the successive action of angiotensin-converting enzyme 2 and angiotensin-converting enzyme.
    Liu S; Liu J; Miura Y; Tanabe C; Maeda T; Terayama Y; Turner AJ; Zou K; Komano H
    J Neurosci Res; 2014 Sep; 92(9):1178-86. PubMed ID: 24823497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ACE inhibition with captopril retards the development of signs of neurodegeneration in an animal model of Alzheimer's disease.
    AbdAlla S; Langer A; Fu X; Quitterer U
    Int J Mol Sci; 2013 Aug; 14(8):16917-42. PubMed ID: 23959119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease.
    Hemming ML; Patterson M; Reske-Nielsen C; Lin L; Isacson O; Selkoe DJ
    PLoS Med; 2007 Aug; 4(8):e262. PubMed ID: 17760499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-converting enzyme overexpression in myelomonocytes prevents Alzheimer's-like cognitive decline.
    Bernstein KE; Koronyo Y; Salumbides BC; Sheyn J; Pelissier L; Lopes DH; Shah KH; Bernstein EA; Fuchs DT; Yu JJ; Pham M; Black KL; Shen XZ; Fuchs S; Koronyo-Hamaoui M
    J Clin Invest; 2014 Mar; 124(3):1000-12. PubMed ID: 24487585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aβ43 is the earliest-depositing Aβ species in APP transgenic mouse brain and is converted to Aβ41 by two active domains of ACE.
    Zou K; Liu J; Watanabe A; Hiraga S; Liu S; Tanabe C; Maeda T; Terayama Y; Takahashi S; Michikawa M; Komano H
    Am J Pathol; 2013 Jun; 182(6):2322-31. PubMed ID: 23562443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripherally derived angiotensin converting enzyme-enhanced macrophages alleviate Alzheimer-related disease.
    Koronyo-Hamaoui M; Sheyn J; Hayden EY; Li S; Fuchs DT; Regis GC; Lopes DHJ; Black KL; Bernstein KE; Teplow DB; Fuchs S; Koronyo Y; Rentsendorj A
    Brain; 2020 Jan; 143(1):336-358. PubMed ID: 31794021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin-converting enzyme converts amyloid beta-protein 1-42 (Abeta(1-42)) to Abeta(1-40), and its inhibition enhances brain Abeta deposition.
    Zou K; Yamaguchi H; Akatsu H; Sakamoto T; Ko M; Mizoguchi K; Gong JS; Yu W; Yamamoto T; Kosaka K; Yanagisawa K; Michikawa M
    J Neurosci; 2007 Aug; 27(32):8628-35. PubMed ID: 17687040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer's disease.
    Dong YF; Kataoka K; Tokutomi Y; Nako H; Nakamura T; Toyama K; Sueta D; Koibuchi N; Yamamoto E; Ogawa H; Kim-Mitsuyama S
    FASEB J; 2011 Sep; 25(9):2911-20. PubMed ID: 21593435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of steady-state beta-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme.
    Eckman EA; Adams SK; Troendle FJ; Stodola BA; Kahn MA; Fauq AH; Xiao HD; Bernstein KE; Eckman CB
    J Biol Chem; 2006 Oct; 281(41):30471-8. PubMed ID: 16912050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Angiotensin converting enzyme and Alzheimer's disease].
    Kugaevskaia EV
    Biomed Khim; 2013; 59(1):5-24. PubMed ID: 23650720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A clinical dose of angiotensin-converting enzyme (ACE) inhibitor and heterozygous ACE deletion exacerbate Alzheimer's disease pathology in mice.
    Liu S; Ando F; Fujita Y; Liu J; Maeda T; Shen X; Kikuchi K; Matsumoto A; Yokomori M; Tanabe-Fujimura C; Shimokata H; Michikawa M; Komano H; Zou K
    J Biol Chem; 2019 Jun; 294(25):9760-9770. PubMed ID: 31072831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plaque-associated overexpression of insulin-degrading enzyme in the cerebral cortex of aged transgenic tg2576 mice with Alzheimer pathology.
    Leal MC; Dorfman VB; Gamba AF; Frangione B; Wisniewski T; Castaño EM; Sigurdsson EM; Morelli L
    J Neuropathol Exp Neurol; 2006 Oct; 65(10):976-87. PubMed ID: 17021402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin Converting Enzyme Inhibitors Ameliorate Brain Inflammation Associated with Microglial Activation: Possible Implications for Alzheimer's Disease.
    Torika N; Asraf K; Roasso E; Danon A; Fleisher-Berkovich S
    J Neuroimmune Pharmacol; 2016 Dec; 11(4):774-785. PubMed ID: 27562846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Hypertension and Anti-Hypertensive Treatment on Amyloid-β (Aβ) Plaque Load and Aβ-Synthesizing and Aβ-Degrading Enzymes in Frontal Cortex.
    Ashby EL; Miners JS; Kehoe PG; Love S
    J Alzheimers Dis; 2016; 50(4):1191-203. PubMed ID: 26836178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidative balance in Alzheimer's disease: relationship to APOE, Braak tangle stage, and the concentrations of soluble and insoluble amyloid-β.
    Tayler H; Fraser T; Miners JS; Kehoe PG; Love S
    J Alzheimers Dis; 2010; 22(4):1363-73. PubMed ID: 20930272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impacts of aging and amyloid-β deposition on plasminogen activators and plasminogen activator inhibitor-1 in the Tg2576 mouse model of Alzheimer's disease.
    Bi Oh S; Suh N; Kim I; Lee JY
    Brain Res; 2015 Feb; 1597():159-67. PubMed ID: 25454795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin-converting enzyme as a potential target for treatment of Alzheimer's disease: inhibition or activation?
    Zou K; Michikawa M
    Rev Neurosci; 2008; 19(4-5):203-12. PubMed ID: 19145983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neprilysin deficiency alters the neuropathological and behavioral phenotype in the 5XFAD mouse model of Alzheimer's disease.
    Hüttenrauch M; Baches S; Gerth J; Bayer TA; Weggen S; Wirths O
    J Alzheimers Dis; 2015; 44(4):1291-302. PubMed ID: 25408216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.